CPHI Podcast Series: Digitalisation of API Supply Chains
Even before the COVID-19 pandemic, the pharmaceutical manufacturing sector was adopting digital technology to save time, cut costs and increase efficiencies in the value chain.
Nevertheless, many digital investments were seen as experimental projects which would likely reap dividends in future years rather than the immediate present. It has taken a global pandemic to fundamentally change this outlook, as pharma firms renew their enthusiasm for digital solutions.
In this interview with Stefan Schmidinger, Partner at Kemiex and Florian Hildebrand, Managing Partner at Qualifyze, we not only discuss the vast array of challenges and opportunities around the ongoing digital transformation in pharmaceutical ingredient supply chains but also the effect a hugely traumatic 2020 had on the ingredients manufacturing sector’s perception of digitalisation and whether it has speeded up companies’ take up of new technologies.
Stefan Schmidinger, Kemiex
Florian Hildebrand, Qualifyze
Related News
-
News AI-powered therapy offers hope for rare familial polyposis
Recursion Pharmaceuticals has announced promising results from its ongoing early- to mid-stage trial evaluating its AI-powered treatment, REC-4881, for familial adenomatous polyposis (FAP).
-
News CPHI Podcast Series: AI transforming pharma manufacturing
This episode explores how AI is revolutionising the pharmaceutical industry, from "smart factories" to seamless supply chain integration, and discuss the transformative advancements shaping the next decade.
-
News AstraZeneca invests in AI-led research agreement with China's CSPC, up to US$5.3 billion
Anglo-Swedish pharmaceutical giant AstraZeneca announced they have signed a deal with China’s CSPC Pharmaceutical Group worth up to US$5.3 billion to drive AI-led research development of therapies for chronic conditions.
-
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News How GLP-1 agonists are reshaping drug delivery innovations
GLP-1 agonist drug products like Ozempic, Wegovy, and Mounjaro have taken the healthcare industry by storm in recent years. Originally conceived as treatment for Type 2 diabetes, the weight-loss effects of these products have taken on unprecedented int... -
News 2025 Pharma Trends Outlook: Collaborative Pharma – A New Era of Supply Chains
A new year, a new Pharma Trends Outlook report! The 2025 Pharma Trends Outlook report examines key changes expected in the pharmaceutical industry for the coming year, particularly in regards to the supply chain.
-
News AI-driven drug discovery model sets new accuracy prediction benchmark
Iambic Therapeutics, an Nvidia-backed biotech based in London, have stated that their AI drug discovery model named ‘Enchant’ demonstrates the potential to reduce the time and cost associated with new drug development.
-
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma.